Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
2.
Rev Esp Enferm Dig ; 112(6): 491-500, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32450708

ABSTRACT

Bariatric endoscopy (BE) encompasses a number of techniques -some consolidated, some under development- aiming to contribute to the management of obese patients and their associated metabolic diseases as a complement to dietary and lifestyle changes. To date different intragastric balloon models, suture systems, aspiration methods, substance injections and both gastric and duodenal malabsorptive devices have been developed, as well as endoscopic procedures for the revision of bariatric surgery. Their ongoing evolution conditions a gradual increase in the quantity and quality of scientific evidence about their effectiveness and safety. Despite this, scientific evidence remains inadequate to establish strong grades of recommendation allowing a unified perspective on prophylaxis in BE. This dearth of data conditions leads, in daily practice, to frequently extrapolate the measures that are used in bariatric surgery (BS) and/or in general therapeutic endoscopy. In this respect, this special article is intended to reach a consensus on the most common prophylactic measures we should apply in BE. The methodological design of this document was developed while attempting to comply with the following 5 phases: Phase 1: delimitation and scope of objectives, according to the GRADE Clinical Guidelines. Phase 2: setup of the Clinical Guide-developing Group: national experts, members of the Grupo Español de Endoscopia Bariátrica (GETTEMO, SEED), SEPD, and SECO, selecting 2 authors for each section. Phase 3: clinical question form (PICO): patients, intervention, comparison, outcomes. Phase 4: literature assessment and synthesis. Search for evidence and elaboration of recommendations. Based on the Oxford Centre for Evidence-Based Medicine classification, most evidence in this article will correspond to level 5 (expert opinions without explicit critical appraisal) and grade of recommendation C (favorable yet inconclusive recommendation) or D (inconclusive or inconsistent studies). Phase 5: External review by experts. We hope that these basic preventive measures will be of interest for daily practice, and may help prevent medical and/or legal conflicts for the benefit of patients, physicians, and BE in general.


Subject(s)
Bariatric Surgery , Gastric Balloon , Endoscopy , Evidence-Based Medicine , Humans , Obesity/prevention & control
4.
Rev Esp Enferm Dig ; 111(10): 812, 2019 Oct.
Article in English | MEDLINE | ID: mdl-30963772

ABSTRACT

A 51 years-old male with several family history of gastric cancer, who was studied one year before for dyspepsia. A new gastroscopy was done that objectified in the greater curvature, a sessile polyp with slightly depressed center and a villous crypt pattern with Narrow Band Imaging. The histopathology study shown a horizontalization of the basal glands and basal dysplasia, compatible with serrated adenoma. A 51 year-old male with a family history of gastric cancer was studied for one year due to dyspepsia. A new gastroscopy was performed that identified a sessile polyp with a slightly depressed center and a villous crypt pattern in the greater curvature via narrow band imaging. The histopathology study showed horizontal basal glands and basal dysplasia, which was compatible with serrated adenoma.


Subject(s)
Adenoma/diagnostic imaging , Gastroscopy , Stomach Neoplasms/diagnostic imaging , Adenoma/pathology , Humans , Male , Middle Aged , Stomach Neoplasms/pathology
20.
Gastroenterol. hepatol. (Ed. impr.) ; 34(1): 24-28, ene. 2011.
Article in Spanish | IBECS | ID: ibc-92601

ABSTRACT

La hemorragia digestiva baja severa es una complicación poco frecuente en la enfermedad de Crohn. Presentamos 3 pacientes con enfermedad de Crohn, de diferente localización que desarrollaron una enterorragia severa, con necesidad transfusional múltiple y que respondieron favorablemente a la administración de infliximab, consiguiendo el cese de la hemorragia que comprometía la vida del paciente y evitando una resección quirúrgica de urgencia que parecía inevitable para la resolución del episodio hemorrágico. Sobre la base de esta experiencia clínica y tras revisar la literatura comparando infliximab con otras opciones farmacológicas, consideramos este fármaco, como primera opción terapéutica a emplear en pacientes con enfermedad de Crohn, que presenten una hemorragia digestiva severa, evitando la cirugía en algunos casos, si conseguimos que la hemorragia ceda por rápida cicatrización de las profundas ulceraciones mucosas, responsables del cuadro hemorrágico (AU)


Severe lower gastrointestinal (GI) bleeding is an infrequent complication in Crohn's disease. We report the cases of three patients with Crohn's disease, localized in distinct areas, who developed severe enterorrhagia requiring multiple transfusions. All three patients responded favorably to infliximab administration, which resolved the life-threatening hemorrhages and avoided emergency surgical resection, which had seemed inevitable. Based on this clinical experience and a review of the literature comparing infliximab with other pharmacological options, we believe that this drug should be the treatment of choice in patients with Crohn's disease who develop severe lower gastrointestinal bleeding. This strategy can, in some cases, avoid surgery if the bleeding stops due to rapid healing of the deep mucosal lesions causing the hemorrhagic episode (AU)


Subject(s)
Humans , Male , Female , Young Adult , Adult , Antibodies, Monoclonal/therapeutic use , Crohn Disease/complications , Gastrointestinal Hemorrhage/etiology , Gastrointestinal Hemorrhage/drug therapy , Severity of Illness Index , Tumor Necrosis Factor-alpha
SELECTION OF CITATIONS
SEARCH DETAIL
...